Dr. Reddy's Laboratories Limited (RDY) 株式分析

企業概要

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical entity serving markets across North America, Europe, India, Russia, and other international regions through its subsidiaries. The company functions within the Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on producing both branded and generic medications alongside specialized pharmaceutical services. This pharmaceutical giant employs a substantial workforce of 27,811 individuals to support its global operations and manufacturing capabilities. The entity holds a market capitalization of $11.05B and reported an annual revenue of $345.83B over the trailing twelve months, indicating a significant scale within the specialized drug manufacturing landscape. These financial dimensions suggest that the company possesses a substantial operational footprint capable of influencing supply dynamics within the global generic and specialty pharmaceutical supply chain.

財務健全性

The company reported a total revenue of $345.83B, with a net income of $56.59B and an EBITDA of $84.79B for the trailing twelve-month period. The substantial gap between the $345.83B revenue and the $56.59B net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, absorb approximately $289.24B of gross revenue before arriving at the bottom line. Free cash flow stands at $13.47B, which indicates a robust capacity to fund capital expenditures, reduce debt, or pursue strategic acquisitions without relying on external financing. The firm maintains a cash reserve of $82.59B against total debt of $67.73B, resulting in a debt-to-equity ratio of 18.03 that reflects a balance sheet carrying significant leverage relative to its equity base. Despite the high debt figure, the current ratio of 1.88 suggests adequate short-term liquidity, as current assets are more than double current liabilities, ensuring the ability to meet obligations due within a year. Return on Equity is measured at 16.1% while Return on Assets stands at 8.0%, metrics that collectively demonstrate management's effectiveness in generating profits from shareholder capital and utilizing the total asset base to drive earnings.

バリュエーション評価

The trailing twelve-month P/E ratio is 18.14, whereas the forward P/E is projected at 23.73, implying that the market anticipates a period of earnings compression or slower growth relative to current profitability levels. The price-to-book ratio of 2.77 indicates that the market values the company at a significant premium over its net asset book value, reflecting expectations of future growth or intangible brand value. Alternative valuation metrics such as the price-to-sales ratio of 0.03 and an EV/EBITDA of -0.01 suggest a valuation structure heavily influenced by the company's debt load and specific accounting adjustments rather than traditional earnings multiples. The stock has traded within a 52-week range between a low of $12.26 and a high of $16.17, with the current valuation sitting within this historical band and reflecting recent price fluctuations. With a beta of 0.30, the stock exhibits low price volatility relative to the broader market, suggesting that its share price is less sensitive to general market movements compared to large-cap peers.

Growth & Income

Revenue growth over the past year stands at 4.4%, while earnings growth has declined by 14.3% year over year, indicating that profitability is expanding at a significantly slower pace than top-line sales. The company distributes a dividend yield of 0.7% with a payout ratio of 11.8%, a conservative figure that suggests the dividend is highly sustainable given the earnings base. Because the payout ratio is so low relative to net income, the company retains the majority of its earnings to reinvest in research, development, and operational expansion rather than prioritizing high dividend distributions. This growth and income profile highlights a strategy focused on organic expansion and debt management rather than immediate shareholder yield, as evidenced by the modest dividend yield and the divergence between revenue and earnings growth rates.